We are live on
!
Find out more
DP
Diadema Partners Portfolio holdings
AUM
$588M
1-Year Est. Return
182.75%
This Fund
S&P 500
This Quarter
Est. Return
+0.81%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$328M
AUM Growth
-$55.1M
(-14%)
Cap. Flow
-$44.7M
Cap. Flow
% of AUM
-13.62%
Top 10 Holdings %
Top 10 Hldgs %
42.21%
Holding
136
New
34
Increased
27
Reduced
16
Closed
41
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$14.8M |
| 2 |
SLNO
Soleno Therapeutics
SLNO
|
+$14.3M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$8.24M |
| 4 |
TG Therapeutics
TGTX
|
+$6.09M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$4.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$13.5M |
| 2 |
argenx
ARGX
|
+$3.66M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$3.54M |
| 4 |
Eli Lilly
LLY
|
+$3.49M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
+$2.65M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 49.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SAGE
126
DELISTED
Sage Therapeutics
SAGE
| – | – |
-183,466
| Closed | -$1.46M |
|
|
FLNA
127
CALL
Filana Therapeutics
FLNA
$48.8M
| – | – |
-300,000
| Closed | -$450K |
|
|
FLNA
128
PUT
Filana Therapeutics
FLNA
$48.8M
| – | – |
-9,900
| Closed | -$14.8K |
|
129
Sagimet Biosciences
SGMT
$439M
| – | – |
-46,019
| Closed | -$150K |
|
|
SLNO
130
CALL
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-219,400
| Closed | -$15.7M |
|
|
SLNO
131
PUT
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-217,000
| Closed | -$15.5M |
|
|
SWTX
132
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-60,000
| Closed | -$2.65M |
|
|
UBX
133
CALL
DELISTED
Unity Biotechnology
UBX
| – | – |
-346,900
| Closed | -$361K |
|
|
UBX
134
PUT
DELISTED
Unity Biotechnology
UBX
| – | – |
-215,200
| Closed | -$224K |
|
|
VERV
135
CALL
DELISTED
Verve Therapeutics
VERV
| – | – |
-116,900
| Closed | -$534K |
|
136
CALL
Viking Therapeutics
VKTX
$3.7B
| – | – |
-50,000
| Closed | -$1.21M |
|
Similar funds
MC
PFG
FMI
EGWAG
PFG
GIM
FL
BA
Diadema Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Diadema Partners held 136 positions worth $328M, down 14% from $383M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Diadema Partners withdrew a net $44.7M in Q2 2025, closing 41 positions and reducing 16 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $3.54M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 33% a quarter earlier.
Against the trend, Diadema Partners opened a new position in Amgen worth $14.5M.
- Diadema Partners's largest Q2 2025 buy was Amgen: 52,100 shares worth $14.5M.
- Diadema Partners added most to Soleno Therapeutics in Q2 2025, an estimated $14.3M increase.
- Diadema Partners's biggest Q2 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $13.5M.
- Diadema Partners fully exited Alnylam Pharmaceuticals in Q2 2025, selling an estimated $3.54M.
- Diadema Partners's ten largest holdings make up 42% of its $328M portfolio in Q2 2025.
- Diadema Partners opened 34 new positions and closed 41 in Q2 2025.
- Diadema Partners's portfolio value fell 14% quarter-over-quarter to $328M.
Based on Diadema Partners's 13F filing for Q2 2025, filed 14 Aug 2025.